LATS1 and mesothelioma: We found RASSF7 amplification in 39 mesotheliomas, NF2 mutations in 24, LATS2 mutations in 6 and LATS1 in 2, so that non-overlapping lesions in Hippo pathways were present in 52/121 mesotheliomas (43%) and a further 9 mesothelioma had more than one lesion (total 50%) (Fig. 2).